Beqvez

Brand (proprietary) name

BEQVEZ

Generic (nonproprietary) name

No authoritative public data was located for this field.

Active ingredient(s)

No authoritative public data was located for this field.

Strength(s)

No authoritative public data was located for this field.

Dosage form(s)

No authoritative public data was located for this field.

Route(s)

No authoritative public data was located for this field.

Manufacturer / labeler

Pfizer Laboratories Div Pfizer Inc

Product class

Biologic (BLA) (derived from FDA marketing category)

Marketing category

BLA

Application number(s)

BLA125786

Earliest marketing start

May 2, 2024

Products / packages indexed

4 / 4

Also searchable as: BEQVEZ · fidanacogene elaparvovec-dzkt

Prescribing information on DailyMed (NLM)

• C9172CC-code: Hospital outpatient (OPPS) codesTerminated Dec 31, 2024Derived calculation

  Injection, fidanacogene elaparvovec-dzkt, per therapeutic dose

  Derived: 4 of 4 NDC package(s) for this drug appear in the CMS NDC–HCPCS crosswalk for C9172. CMS quarters Q4 2024 – Q4 2024Not in the latest CMS crosswalk.

  C-codes are temporary codes for hospital outpatient use under the Medicare Outpatient Prospective Payment System, including pass-through drugs and biologicals (many in C9xxx) and devices. They are generally not reported by physician offices; other payers may not recognize them.

• J1414

No authoritative public data was located for this field.

Home infusion per diem (S-codes)

Medicare

Not payable by Medicare — CMS coverage code I (all 2 codes)

Part B pricing indicator

00 — Not separately priced by Part B (all 2 codes)

National payment amount

No authoritative public data was located for this field.

Which Medicare benefit pays for this drug?

• Coverage documents for J1414 NCDs, LCDs, and Billing & Coding articles in the CMS Medicare Coverage Database that mention “J1414”. Covered diagnosis codes are listed in the articles.
• Self-administered drug (SAD) exclusion lists Drugs each MAC excludes from “incident to” Part B coverage because they are usually self-administered.

No current Medicare Billing and Coding article lists C9172, J1414.

• FDA NDC Directory data is submitted by labelers; FDA notes that inclusion does not mean the information was verified or that a product is approved, covered, or reimbursable.
• HCPCS links are derived from CMS NDC–HCPCS crosswalks, which support ASP-based Part B payment and are not a complete list of billable NDCs.
• Product class (brand, generic, biosimilar) is derived from the FDA marketing category and Purple Book license type, not from a commercial compendium.
• Payment limits are Medicare Part B national limits; they do not reflect payer contracts, OPPS rates, 340B pricing, or acquisition cost.
• Home infusion per diem S-codes are matched by therapy category from the FDA pharmacologic class and route, not from a CMS crosswalk. Payers choose which per diem codes they accept, and the right code can depend on the dosing schedule, infusion method, or daily volume.